NCT06400524

Assessment of Cardiac Function, Microvascular Function and Cardiac Perfusion in Different Disease Stages of Hypertrophic Cardiomyopathy

Assessment of Myocardial Function, (Peripheral) Endothelial Function and Perfusion in Early and Advanced Disease Stages of Hypertrophic Cardiomyopathy
Amsterdam UMC, location VUmc·ClinicalTrials.govRecruiting
View on ClinicalTrials.gov
Study focus
Study type
Observational
Sponsor & location
Primary sponsor
Amsterdam UMC, location VUmc
Location
Amsterdam, Netherlands
Timeline & enrollment
Phase
N/A
Start date
May 01, 2024
End date
May 01, 2026
Enrollment
100 participants
Primary outcome

myocardial blood flow,peripheral endothelial function

Summary

Hypertrophic cardiomyopathy (HCM) is a genetic disorder characterized by asymmetric
 hypertrophy of the heart in absence of loading conditions like hypertension. The genetic
 mutation underlying HCM sets in motion a cascade of functional and metabolic changes
 ultimately leading to disease. HCM patients often have microvascular dysfunction and
 myocardial perfusion deficits, of which the aetiology has not been elucidated. Whether these
 changes are secondary to remodelling or primarily caused by endothelial dysfunction is
 unclear. As the pathomechanism of HCM is thought to be a cascade of changes, it is important
 to gain more insight in the perfusion and endothelial function changes throughout different
 stages of disease: no phenotype, mild phenotype, and advanced HCM phenotype. In this study we
 aim to investigate these changes in the two most common genetic mutations.

ICD-10 classifications
Obstructive hypertrophic cardiomyopathyOther hypertrophic cardiomyopathyCardiomyopathyCardiomyopathy, unspecifiedCardiomyopathy in diseases classified elsewhere
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06400524
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06400524 through Pure Global AI's free database. This phase not specified trial is sponsored by Amsterdam UMC, location VUmc and is currently Recruiting. The study focuses on Hypertrophic Cardiomyopathy,Hypertrophic Cardiomyopathy, Obstructive. Target enrollment is 100 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.